These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 12841871)

  • 1. Combined effects of prostaglandin E receptor subtype EP1 and subtype EP4 antagonists on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice.
    Kitamura T; Itoh M; Noda T; Tani K; Kobayashi M; Maruyama T; Kobayashi K; Ohuchida S; Sugimura T; Wakabayashi K
    Cancer Sci; 2003 Jul; 94(7):618-21. PubMed ID: 12841871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of azoxymethane-induced colon cancer development in rats by a prostaglandin E receptor EP1-selective antagonist.
    Niho N; Mutoh M; Kitamura T; Takahashi M; Sato H; Yamamoto H; Maruyama T; Ohuchida S; Sugimura T; Wakabayashi K
    Cancer Sci; 2005 May; 96(5):260-4. PubMed ID: 15904466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis.
    Watanabe K; Kawamori T; Nakatsugi S; Ohta T; Ohuchida S; Yamamoto H; Maruyama T; Kondo K; Ushikubi F; Narumiya S; Sugimura T; Wakabayashi K
    Cancer Res; 1999 Oct; 59(20):5093-6. PubMed ID: 10537280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prostaglandin E2 receptor subtype EP1-selective antagonist, ONO-8711, suppresses 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis.
    Makita H; Mutoh M; Maruyama T; Yonemoto K; Kobayashi A; Fujitsuka H; Toida M; Shibata T; Miyamoto S; Yasui Y; Suzuki R; Wakabayashi K; Tanaka T
    Carcinogenesis; 2007 Mar; 28(3):677-84. PubMed ID: 17052996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development.
    Kawamori T; Uchiya N; Nakatsugi S; Watanabe K; Ohuchida S; Yamamoto H; Maruyama T; Kondo K; Sugimura T; Wakabayashi K
    Carcinogenesis; 2001 Dec; 22(12):2001-4. PubMed ID: 11751431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PGE2 promotes Ca2+-mediated epithelial barrier disruption through EP1 and EP4 receptors in Caco-2 cell monolayers.
    Rodríguez-Lagunas MJ; Martín-Venegas R; Moreno JJ; Ferrer R
    Am J Physiol Cell Physiol; 2010 Aug; 299(2):C324-34. PubMed ID: 20484658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of peripheral administration of a novel selective antagonist for prostaglandin E receptor subtype EP(1), ONO-8711, in a rat model of postoperative pain.
    Omote K; Kawamata T; Nakayama Y; Kawamata M; Hazama K; Namiki A
    Anesth Analg; 2001 Jan; 92(1):233-8. PubMed ID: 11133634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis.
    Mutoh M; Watanabe K; Kitamura T; Shoji Y; Takahashi M; Kawamori T; Tani K; Kobayashi M; Maruyama T; Kobayashi K; Ohuchida S; Sugimoto Y; Narumiya S; Sugimura T; Wakabayashi K
    Cancer Res; 2002 Jan; 62(1):28-32. PubMed ID: 11782353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice.
    Kitamura T; Itoh M; Noda T; Matsuura M; Wakabayashi K
    Int J Cancer; 2004 Apr; 109(4):576-80. PubMed ID: 14991580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a selective prostaglandin E receptor EP1 antagonist for potential properties in colon carcinogenesis.
    Kawamori T; Uchiya N; Kitamura T; Ohuchida S; Yamamoto H; Maruyama T; Sugimura T; Wakabayashi K
    Anticancer Res; 2001; 21(6A):3865-9. PubMed ID: 11911260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antagonism of the prostaglandin E2 EP1 receptor in MDCK cells increases growth through activation of Akt and the epidermal growth factor receptor.
    Taub M; Parker R; Mathivanan P; Ariff MA; Rudra T
    Am J Physiol Renal Physiol; 2014 Sep; 307(5):F539-50. PubMed ID: 25007872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development.
    Shoji Y; Takahashi M; Kitamura T; Watanabe K; Kawamori T; Maruyama T; Sugimoto Y; Negishi M; Narumiya S; Sugimura T; Wakabayashi K
    Gut; 2004 Aug; 53(8):1151-8. PubMed ID: 15247185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prostaglandin E2 receptor subtype EP1 receptor antagonist (ONO-8711) reduces hyperalgesia, allodynia, and c-fos gene expression in rats with chronic nerve constriction.
    Kawahara H; Sakamoto A; Takeda S; Onodera H; Imaki J; Ogawa R
    Anesth Analg; 2001 Oct; 93(4):1012-7. PubMed ID: 11574375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostaglandin E prevents indomethacin-induced gastric and intestinal damage through different EP receptor subtypes.
    Kunikata T; Araki H; Takeeda M; Kato S; Takeuchi K
    J Physiol Paris; 2001; 95(1-6):157-63. PubMed ID: 11595431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostanoid EP1 receptor as the target of (-)-epigallocatechin-3-gallate in suppressing hepatocellular carcinoma cells in vitro.
    Jin J; Chang Y; Wei W; He YF; Hu SS; Wang D; Wu YJ
    Acta Pharmacol Sin; 2012 May; 33(5):701-9. PubMed ID: 22555372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effect of a prostaglandin E receptor subtype EP(1) selective antagonist, ONO-8713, on development of azoxymethane-induced aberrant crypt foci in mice.
    Watanabe K; Kawamori T; Nakatsugi S; Ohta T; Ohuchida S; Yamamoto H; Maruyama T; Kondo K; Narumiya S; Sugimura T; Wakabayashi K
    Cancer Lett; 2000 Aug; 156(1):57-61. PubMed ID: 10840160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells.
    Han C; Michalopoulos GK; Wu T
    J Cell Physiol; 2006 Apr; 207(1):261-70. PubMed ID: 16331686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 16,16-Dimethyl prostaglandin E2 inhibits indomethacin-induced small intestinal lesions through EP3 and EP4 receptors.
    Kunikata T; Tanaka A; Miyazawa T; Kato S; Takeuchi K
    Dig Dis Sci; 2002 Apr; 47(4):894-904. PubMed ID: 11991626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of intrathecal administration of an antagonist for prostaglandin E receptor subtype EP(1) on mechanical and thermal hyperalgesia in a rat model of postoperative pain.
    Omote K; Yamamoto H; Kawamata T; Nakayama Y; Namiki A
    Anesth Analg; 2002 Dec; 95(6):1708-12, table of contents. PubMed ID: 12456444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostaglandin E2 increases proximal tubule fluid reabsorption, and modulates cultured proximal tubule cell responses via EP1 and EP4 receptors.
    Nasrallah R; Hassouneh R; Zimpelmann J; Karam AJ; Thibodeau JF; Burger D; Burns KD; Kennedy CR; Hébert RL
    Lab Invest; 2015 Sep; 95(9):1044-55. PubMed ID: 26121313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.